A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia-Reference-Cited by-同舟云学术

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia

Published:2022-08-23 Issue:2 Volume:200 Page:229-239
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Mahlangu Johnny N.¹²³^ORCID,Lamas Jose Luis⁴,Morales Juan Cristobal⁴,Malan Daniel R.⁵,Šalek Silva Zupančić⁶,Wang Michael⁷,Boggio Lisa N.⁸,Hegemann Inga⁹,Mital Andrzej¹⁰,Cardinal Matthew,Zhu Tong¹¹,Sun Pengling¹¹,Arkin Steven¹¹

Affiliation:

1. University of the Witwatersrand Johannesburg South Africa

2. National Health Laboratory Service Johannesburg South Africa

3. Charlotte Maxeke Johannesburg Academic Hospital Johannesburg South Africa

4. Hospital Dr. Sótero del Río Puente Alto Santiago Chile

5. Phoenix Pharma, Mount Croix Port Elizabeth South Africa

6. University Hospital Centre Zagreb Zagreb Croatia

7. University of Colorado Hemophilia and Thrombosis Center Aurora Colorado USA

8. Rush Hemophilia and Thrombophilia Center Chicago Illinois USA

9. Haemophilia Comprehensive Care Center University Hospital Zurich Switzerland

10. Medical University of Gdańsk Gdańsk Poland

11. Pfizer Worldwide Research and Development Cambridge Massachusetts USA